Vericel Co. (NASDAQ:VCEL) Director Sells $156,250.00 in Stock

Vericel Co. (NASDAQ:VCEL - Get Free Report) Director Robert L. Md Zerbe sold 2,500 shares of Vericel stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $62.50, for a total transaction of $156,250.00. Following the completion of the transaction, the director now directly owns 26,595 shares of the company's stock, valued at $1,662,187.50. This trade represents a 8.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Vericel Trading Down 1.9 %

Shares of NASDAQ:VCEL traded down $1.14 during mid-day trading on Tuesday, reaching $57.51. The stock had a trading volume of 207,123 shares, compared to its average volume of 403,842. The firm has a market cap of $2.84 billion, a PE ratio of 958.66 and a beta of 1.72. The firm has a 50 day simple moving average of $57.84 and a two-hundred day simple moving average of $51.19. Vericel Co. has a twelve month low of $39.12 and a twelve month high of $63.00.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Canaccord Genuity Group boosted their price target on shares of Vericel from $64.00 to $67.00 and gave the stock a "buy" rating in a research report on Monday, February 3rd. HC Wainwright restated a "buy" rating and set a $60.00 price target on shares of Vericel in a report on Wednesday, January 15th. StockNews.com raised shares of Vericel from a "sell" rating to a "hold" rating in a research report on Tuesday, December 24th. BTIG Research boosted their target price on shares of Vericel from $56.00 to $66.00 and gave the stock a "buy" rating in a research report on Tuesday, November 26th. Finally, Stephens reissued an "overweight" rating and issued a $65.00 target price on shares of Vericel in a research report on Wednesday, January 15th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $63.14.

Institutional Trading of Vericel

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Wellington Management Group LLP raised its stake in Vericel by 214.0% in the third quarter. Wellington Management Group LLP now owns 587,857 shares of the biotechnology company's stock valued at $24,837,000 after purchasing an additional 400,667 shares in the last quarter. Stifel Financial Corp grew its holdings in shares of Vericel by 40.0% during the third quarter. Stifel Financial Corp now owns 28,073 shares of the biotechnology company's stock worth $1,186,000 after purchasing an additional 8,020 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Vericel by 0.8% in the third quarter. Geode Capital Management LLC now owns 1,154,053 shares of the biotechnology company's stock valued at $48,768,000 after acquiring an additional 9,613 shares during the last quarter. Intech Investment Management LLC bought a new stake in Vericel in the third quarter valued at approximately $563,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in shares of Vericel by 4.6% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,079,048 shares of the biotechnology company's stock worth $45,590,000 after buying an additional 47,108 shares in the last quarter.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.